Drug intelligence / Profile preview

HY-0011

Development stage: Preclinical
Lead developer: Huiyu Anlaibo
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

HY-0011 is an mRNA-based vaccine candidate being developed by Huiyu Anlaibo Pharmaceutical Technology, a subsidiary of Sichuan Huiyu Pharmaceutical. The drug is currently in the IND-enabling stage of development. As an mRNA vaccine, it is designed to deliver genetic sequences encoding specific antigens into host cells, which then translate the mRNA to produce the antigen and trigger an immune response. While the specific target antigen and primary therapeutic indication have not been disclosed in the company's high-level pipeline summaries, the candidate represents part of Huiyu's expansion into innovative biologic platforms.

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on HY-0011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY-0011.

Explore the full profile